10-K: Dynavax Technologies Corp. Reports Strong HEPLISAV-B Growth in 2023, Advances Pipeline

Dynavax Technologies Corp. saw a 69% increase in HEPLISAV-B revenue in 2023 and is progressing its shingles, Tdap, and plague vaccine programs.

Summary

• Dynavax Technologies Corporation reported a 69% increase in HEPLISAV-B product revenue in the U.S., reaching $213.3 million for the year ended December 31, 2023.
• The company's HEPLISAV-B market share in the U.S. increased to approximately 42%, with significant gains in the retail pharmacy and Integrated Delivery Networks segments.
• A supplemental Biologic License Application for HEPLISAV-B vaccination of adults on hemodialysis is under priority review by the FDA, with a decision expected by May 13, 2024.
• Dynavax is advancing its clinical pipeline, including a Phase 1/2 trial for its shingles vaccine candidate, Z-1018, expected to begin in the first half of 2024.
• A Phase 2 human challenge study for the Tdap-1018 vaccine candidate is planned for the second half of 2024, pending completion of an independent study.
• Top-line data for the Phase 2 clinical trial of the plague vaccine candidate is anticipated in 2024.
• The company generated $100.6 million in cash from operating activities in 2023 and ended the year with $742.3 million in cash, cash equivalents, and marketable securities.
• Dynavax reported a net loss of $6.4 million for the year ended December 31, 2023.
• The company did not recognize any CpG 1018 adjuvant net product revenue in 2023, as all obligations under existing agreements were completed by the end of 2022.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth for HEPLISAV-B and advancements in the pipeline. However, the net loss and reliance on third parties for manufacturing introduce some caution. The company's strong cash position and strategic focus are positive indicators.

Positives

• HEPLISAV-B is the only two-dose hepatitis B vaccine for adults approved in the U.S., EU, and Great Britain.
• The company is actively leveraging the CDC's ACIP recommendation for universal hepatitis B vaccination in adults aged 19-59.
• The company has a strong cash position of $742.3 million.
• The company is advancing a diversified pipeline of vaccine candidates leveraging its CpG 1018 adjuvant.
• The company has a second qualified supplier to produce CpG 1018 adjuvant.

Negatives

• The company reported a net loss of $6.4 million for the year ended December 31, 2023.
• The company did not recognize any CpG 1018 adjuvant net product revenue in 2023.
• The company relies on third parties for manufacturing and supply of its products.
• The company faces significant competition in the hepatitis B vaccine market.
• The company's financial commitments for manufacturing and supply capacity might outpace actual demand for its products.

Risks

• The company faces significant competition in the hepatitis B vaccine market, which could impact HEPLISAV-B's commercial success.
• The company relies on third parties for manufacturing and supply, which could lead to disruptions and delays.
• The company's financial commitments for manufacturing and supply capacity might outpace actual demand for its products.
• The company's financial results may vary significantly from quarter to quarter, which could affect the stock price.
• The company may require substantial additional capital to finance its operations if it does not successfully commercialize HEPLISAV-B or launch new products.
• The company is subject to ongoing regulatory obligations and continued regulatory review for HEPLISAV-B and other product candidates.
• Clinical trials for the company's product candidates may be extended, delayed, or not completed at all.
• The company may not succeed in establishing and maintaining collaborative relationships, which could limit its ability to develop and commercialize products.
• The company's stock price is subject to volatility, and your investment may suffer a decline in value.
• The company is subject to various healthcare fraud and abuse laws, which could result in penalties if not complied with.

Future Outlook

The company aims to increase HEPLISAV-B market share, maximize the total addressable market based on the ACIP recommendation, and advance its pipeline of vaccine candidates. They also plan to pursue external opportunities to leverage their commercial capabilities and prioritize first or best-in-class assets.

Management Comments

• The company believes the ACIP universal recommendation for hepatitis B vaccination will enable a significantly expanded total annual market opportunity of approximately $800 million in the U.S. by 2027.
• The company is well positioned to achieve a majority market share with HEPLISAV-B.
• The company is focused on driving growth in its HEPLISAV-B commercial vaccine, advancing a differentiated vaccine pipeline, and identifying strategic opportunities to accelerate growth.

Industry Context

The document highlights the competitive landscape in the vaccine market, particularly for hepatitis B and shingles vaccines. It also notes the increasing emphasis on cost-containment measures by healthcare payors and governments, which could impact pricing and reimbursement for Dynavax's products.

Comparison to Industry Standards

• The document mentions competitors such as GSK, Merck, and VBI in the hepatitis B vaccine market, highlighting HEPLISAV-B's unique two-dose regimen as a competitive advantage.
• The company is also competing with companies like Pfizer, BioNTech, and Curevo in the shingles vaccine space, where Shingrix is the current standard of care.
• The document notes that many competitors have greater financial resources and expertise, which could pose a challenge for Dynavax.
• The company believes its CpG 1018 adjuvant is more effective and sustainable than other adjuvants derived from shark squalene or tree bark.

Stakeholder Impact

• Shareholders: The company's performance and future prospects will impact shareholder value.
• Employees: The company's growth and development will affect employee opportunities and compensation.
• Customers: The company's products will impact healthcare providers and patients.
• Suppliers: The company's manufacturing and supply chain will impact its relationships with suppliers.
• Creditors: The company's financial performance will impact its ability to meet debt obligations.

Next Steps

• Initiate a Phase 1/2 trial for the shingles vaccine candidate, Z-1018, in the first half of 2024.
• Submit an IND to the FDA to support the initiation of the Phase 2 human challenge study of Tdap-1018 in the second half of 2024.
• Anticipate top-line data for the Phase 2 clinical trial of the plague vaccine candidate in 2024.
• Continue to explore ways to enhance the clinical profile of HEPLISAV-B.
• Continue to identify other programs where CpG 1018 adjuvant can be utilized.

Key Dates

Keywords

HEPLISAV-B, Hepatitis B vaccine, CpG 1018 adjuvant, Vaccine, Shingles vaccine, Tdap vaccine, Plague vaccine, Clinical trials, Biopharmaceutical, Immunization